Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

SION-719

Other · developed by Sionna Therapeutics

Phase 2 Most advanced trial (none active)
SION Developer
1 Registered trials

What is SION-719?

SION-719 is a drug studied in cystic fibrosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Respiratory
Developer
Sionna Therapeutics Inc. (SION)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07108153 Phase 2 Cystic Fibrosis (CF) Completed SION

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cystic Fibrosis (CF)

More from Sionna Therapeutics

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SION page.

Follow SION, the company behind SION-719

See SION's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SION catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.